Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May:23:42-45.
doi: 10.1016/j.jdcr.2022.03.008. Epub 2022 Mar 12.

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series

Fabrizio Martora  1 , Vincenzo Picone  1 , Gabriella Fabbrocini  1 , Claudio Marasca  1
Affiliations
Case Reports

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series

Fabrizio Martora et al. JAAD Case Rep. 2022 May.
No abstract available

Keywords: COVID-19; HS, Hidradenitis suppurativa; IHS4; IHS4, International Hidradenitis Suppurativa Severity Score System; hidradenitis suppurativa; vaccine.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
A, Patient 1 with nodules and fistulas in the axillary region before vaccination. B, Patient 1 with new inflammatory nodules localized mainly to the axillary region after the first and second dose of COVID-19 vaccination.
Fig 2
Fig 2
A, Patient 2 with nodules and fistulas in the intramammary region before vaccination. B, Patient 2 with flare-ups of manifestations and new inflammatory nodules and fistulous tracts after the first and second dose of COVID-19 vaccination.
Fig 3
Fig 3
A, Patient 3 with nodules, fistulas, and abscesses in the axillary region before vaccination. B, Patient 3 with flare-ups of manifestations and new inflammatory nodules, abscesses, and fistulas after third dose of COVID-19 vaccination.
See this image and copyright information in PMC

References

    1. Marasca C., Annunziata M.C., Napolitano M., Fabbrocini G. Unconventional therapies for hidradenitis suppurativa. Expert Rev Clin Pharmacol. 2018;11(9):879–887. doi: 10.1080/17512433.2018.1509706. - DOI - PubMed
    1. Wack S., Patton T., Ferris L.K. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol. 2021;85(5):1274–1284. doi: 10.1016/j.jaad.2021.07.054. - DOI - PMC - PubMed
    1. Marasca C., Ruggiero A., Napolitano M., Fabbrocini G., Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853. doi: 10.1016/j.mehy.2020.109853. - DOI - PMC - PubMed
    1. Garrido I, Lopes S, Macedo G. Safety of COVID-19 vaccination in inflammatory bowel disease patients on biologic therapy. Preprint. Posted online October 30, 2021. J Crohns Colitis. 10.1093/ecco-jcc/jjab189 - DOI - PMC - PubMed
    1. Giamarellos-Bourboulis E.J., Bettoli V., Jemec G.B.E., et al. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol. 2021;30(suppl 1):18–22. doi: 10.1111/exd.14339. - DOI - PMC - PubMed

Publication types